

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485]

Final Stakeholder List

 UK Clinical Pharmacy Association UK Kidney Association UK Renal Pharmacy Group AS Kalceks (furosemide) AstraZeneca (dapagliflozin) Atnahs pharma (chlortalidone, lisinopril) Aurobindo pharma (amiloride hydrochloride, candesartan, enalapril, 	Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 NHS England lisinopril, Iosartan, olmesartan, perindopril, ramipril, valsartan) Baxter healthcare (furosemide) 	 Genus Pharmaceuticals (targeted-release budesonide) <u>Patient/carer groups</u> Kidney Care UK Kidney Research UK National Kidney Federation Polycystic Kidney Disease Charity South Asian Health Foundation Specialised Healthcare Alliance <u>Healthcare professional groups</u> Association of Renal Technologists British Association of Urological Nurses British Geriatrics Society Royal College of General Practitioners Royal College of Physicians Royal College of Physicians Royal College of Physicians Royal College of Mursing Royal College of Medicine Society for DGH Nephrologists UK Clinical Pharmacy Association UK Kidney Association UK Renal Pharmacy Group Others Department of Health and Social Care 	 All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Association of Renal Industries Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health - Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Association of Primary Care National Pharmacy Association NHS Confederation NHS Wales Joint Commissioning Committee Scottish Medicines Consortium Welsh Government Comparator companies A.Menarini Group (canagliflozin) Advanz pharma (acetazolamide) Amarox (eprosartan, irbesartan, losartan, olmesartan) AS Kalceks (furosemide) AstraZeneca (dapagliflozin) Atnahs pharma (chlortalidone, lisinopril) Aurobindo pharma (amiloride hydrochloride, candesartan, enalapril, furosemide, fosinopril, irbesartan, lisinopril, losartan, olmesartan, perindopril, ramipril, valsartan)

Final stakeholder list for the evaluation of targeted-release budesonide for treating primary IgA nephropathy (review of TA937) [ID6485] Issue date: March 2025

© National Institute for Health and Care Excellence 2025. All rights reserved.

Provisional Consultees	Provisional Commentators (no right to
	submit or appeal)
	- Rochringer Ingelheim (omnegliflezin
	 Boehringer Ingelheim (empagliflozin, telmisartan)
	 Bristol laboratories (lisinopril)
	 Brown & Burk (irbesartan, lisinopril,
	ramipril, telmisartan, losartan)
	 Chemidex pharma (amiloride
	hydrochloride, bumetanide)
	 Daiichi Sankyo (olmesartan)
	Dexcel pharma (enalapril, losartan)
	Essential pharma (amiloride
	hydrochloride)
	Flamingo Pharma (losartan)
	Glenmark pharma (olmesartan,
	perindopril, telmisartan)
	Hameln pharma (furosemide)
	Ipca laboratories (furosemide)
	KrKA UK (candesartan, indapamide,
	losartan, olmesartan, perindopril,
	telmisartan)
	Martindale pharma (captopril)
	Merck Sharp & Dohme (ertugliflozin)
	Morningside healthcare (chlortalidone)
	Neon healthcare (candesartan)
	Novartis (valsartan)
	Organon Pharma (enalapril, losartan)
	Pfizer (quinapril)
	Phoenix healthcare (quinapril)
	Pinewood healthcare (furosemide)
	Proveca (enalapril)
	Roma pharmaceuticals (lisinopril, ramipril)
	Rosemont pharmaceuticals (bumetanide,
	enalapril, furosemide, lisinopril, ramipril)
	 Sandoz (candesartan, losartan, perindopril, ramipril, telmisartan)
	 Sanofi (furosemide, irbesartan, ramipril)
	 Sanon (turosennde, indesanan, rampin) Servier laboratories (indapamide,
	perindopril)
	 Sigma pharmaceuticals (amiloride
	hydrochloride, bendroflumethiazide,
	chlortalidone, indapamide, quinapril)
	 Strides pharma (furosemide, indapamide)
	Takeda (azilsartan)
	 Ten pharma (captopril)


Provisional Consultees	Provisional Commentators (no right to submit or appeal)
	 Thame laboratories (captopril, furosemide) Thornton & Ross (olmesartan) Tillomed laboratories (amiloride hydrochloride, perindopril,) Viatris (bendroflumethiazide, bumetanide, candesartan, enalapril, eprosartan, indapamide, irbesartan, lisinopril, losartan, perindopril, torasemide, trandolapril, valsartan, xipamide) Vifor Pharma (sparsentan) Wockhardt UK (amiloride hydrochloride, captopril, chlortalidone, furosemide, ramipril) Zentiva (indapamide, irbesartan, ramipril, valsartan)
	 <u>Relevant research groups</u> Cochrane Kidney and Transplant Group Genomics England MRC Clinical Trials Unit National Institute for Health Research <u>Associated Public Health groups</u> Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees



Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.